Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07443202 | Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE) | PHASE2 | ENROLLING BY_INVITATION | 155 | — | — | Dec 5, 2025 | Dec 31, 2027 | Mar 2, 2026 | 2 | United States |
Number of patients with treatment related emergent adverse events (TEAEs)
| Arm | Type | Description |
|---|---|---|
| Treatment arm | EXPERIMENTAL | lotilaner - high dose and low dose |
| Control arm | OTHER | Vehicle of lotilaner - high dose and low dose |
| Name | Type | Description |
|---|---|---|
| lotilaner | DRUG | lotilaner |
| Vehicle | DRUG | Vehicle of lotilaner |
Inclusion Criteria: * 18 years of age or older at the time of consent. * Has moderate to severe ocular rosacea * Use of acceptable methods of contraception * Are willing to sign the informed consent form and is deemed capable of complying with the requirements of the study protocol Exclusion Crite...